Abstract
Stroke pathology involves multifactorial pro-death responses, including inflammation, oxidative stress, vascular dysfunction, and activation of necrotic and apoptotic pathways. The interruption of a single specific pathway in defined stroke model systems has not been sufficient to address the multifactorial nature of stroke-induced injuries in the human population. CD36 is a class B scavenger receptor that functions in regulating normal physiological and pathological functions. CD36 pathways are activated by several distinct ligands. Convergence of these pathways results in inflammatory responses and endothelial dysfunction, which may be an underlying cause of cardio- and cerebrovascular diseases. The current review describes receptor CD36-ligand interactions relevant to endothelial function and discusses how targeting CD36 may have therapeutic utility in stroke.
Keywords: CD36, stroke, angiogenesis, inflammation, endothelial dysfunction, pro-death responses, oxidative stress, vascular dysfunction, cerebrovascular diseases, scavenger receptor.
Current Pharmaceutical Design
Title:CD36 as a Therapeutic Target for Endothelial Dysfunction in Stroke
Volume: 18 Issue: 25
Author(s): Sunghee Cho
Affiliation:
Keywords: CD36, stroke, angiogenesis, inflammation, endothelial dysfunction, pro-death responses, oxidative stress, vascular dysfunction, cerebrovascular diseases, scavenger receptor.
Abstract: Stroke pathology involves multifactorial pro-death responses, including inflammation, oxidative stress, vascular dysfunction, and activation of necrotic and apoptotic pathways. The interruption of a single specific pathway in defined stroke model systems has not been sufficient to address the multifactorial nature of stroke-induced injuries in the human population. CD36 is a class B scavenger receptor that functions in regulating normal physiological and pathological functions. CD36 pathways are activated by several distinct ligands. Convergence of these pathways results in inflammatory responses and endothelial dysfunction, which may be an underlying cause of cardio- and cerebrovascular diseases. The current review describes receptor CD36-ligand interactions relevant to endothelial function and discusses how targeting CD36 may have therapeutic utility in stroke.
Export Options
About this article
Cite this article as:
Cho Sunghee, CD36 as a Therapeutic Target for Endothelial Dysfunction in Stroke, Current Pharmaceutical Design 2012; 18 (25) . https://dx.doi.org/10.2174/138161212802002760
DOI https://dx.doi.org/10.2174/138161212802002760 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardioprotective Potential of Iron Chelators and Prochelators
Current Medicinal Chemistry Radiolabelled Probes Targeting Tumor Hypoxia for Personalized Medicine
Current Pharmaceutical Design Biomarkers in Unstable Carotid Plaque: Physiopathology and Prediction
Cardiovascular & Hematological Agents in Medicinal Chemistry Peptide5 Attenuates rtPA Related Brain Microvascular Endothelial Cells Reperfusion Injury via the Wnt/β-Catenin Signalling Pathway
Current Neurovascular Research Inflammatory Cytokines in Acute Ischemic Stroke
Current Pharmaceutical Design Infectious Burden: A New Risk Factor and Treatment Target for Atherosclerosis
Infectious Disorders - Drug Targets Exercise and Cardiac Preconditioning Against Ischemia Reperfusion Injury
Current Cardiology Reviews The Carnitine Transporter Network: Interactions with Drugs
Current Chemical Biology Generation of Human Cardiomyocytes for Cardiac Regenerative Therapies: Differentiation and Direct Reprogramming
Current Pharmaceutical Design Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry Sonic Hedgehog Signaling Activation Promotes Cardioprotective Strategies
Current Signal Transduction Therapy Dexmedetomidine: A Novel Anesthetic Agent for Middle Ear Surgery
Recent Patents on CNS Drug Discovery (Discontinued) Regulation of Angiogenesis by Macrophages, Dendritic Cells, and Circulating Myelomonocytic Cells
Current Pharmaceutical Design Protein Kinase C Isozyme Selective Peptides - A Current View of What they Tell Us About Location and Function of Isozymes in the Heart
Current Pharmaceutical Design Preconditioning of the Myocardium by Volatile Anesthetics
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug
Inflammation & Allergy - Drug Targets (Discontinued) Future of Cardiac Pacemaker – an Update of Biological Pacemaker Patents
Recent Patents on Biomedical Engineering (Discontinued) Novel Cardiovascular Risk Factors and Macrovascular and Microvascular Complications of Diabetes
Current Drug Targets Left Ventricular Hypertrophy in Isolated Aortic Stenosis: Primetime for the Ventricle
Current Pharmaceutical Biotechnology Emerging Risk Factors for Cerebrovascular Disease
Current Drug Targets